A Complete Review On Liposome Based Delivery Of Water-Soluble Drugs.

Authors

  • Bharwad sandipkumar raghubhai
  • Jyoti Verma

Keywords:

model lipid bilayers; bioactive compounds; membrane fluidity; membrane kinetics; essential methods for liposome/vesicle preparation oral; absorption; water-insoluble drugs; bioavailability

Abstract


 In this review article, we learned more about liposomes, a sort of drug delivery system utilised to target a specific tissue for the drug's effects. Liposomes can deliver medications where free medicines cannot because of the structural similarities between the lipid bilayer and the cell membrane. Because of its biocompatibility and capacity to encase hydrophobic molecules in the lipid domain, the liposomal delivery system has attracted attention as one of the noteworthy methods to improve dissolution and consequently absorption in the gastrointestinal (GI) tract. Due to its comparatively vast size, the GI tract's structural instability and low permeability across intestinal epithelia have been some of the disadvantages. In addition, despite the success of parenteral liposomes, there are yet to be any liposomal formulations authorised for oral use. However, the recent decade has seen a sharp rise in the number of published studies, which has led to a resurgence in liposomal oral administration. The majority of this research, however, has primarily involved in vitro tests, and there are not many water-insoluble medications that have in vivo evidence. People who are fairly new to this field of research should find the information in this article particularly useful...

Downloads

Download data is not yet available.

References

1.Alving C.R. Macrophages, as targets for delivery of liposome encapsulated antimicrobial agents. Adv Drug Delivery Rev, (1998); 2.

2.C. J. Chapman Allison, A.C., Gregorius’s, G, 1974. Liposomes as immunological adjuvant. Nature 252, 252.

3.Deamer, D. and Ulster, P., Liposome preparation methods and monitoring liposome fusion. In: Baserga, R., Croce, C. and Royeza, G. (Eds.), Introduction of Macromolecules into viable Mammalian Cells, Alan R. Liss, New York, 1980,pp. 205 220.

4.de Marie, S., Janknegt, R., Bakker-Woudenberg, I.A.J.M.,1994. Clinical use of liposomal and lipid-complexed amphotericin B. J. Antimicrob. Chemother. 33, 907-916.

5.Guo, S.; Huang, L. Nanoparticles Containing Insoluble Drug for Cancer Therapy. Biotechnol. Adv. 2014, 32, 778–788.

6. Allen, T.M.; Cullis, P.R. Liposomal Drug Delivery Systems: From Concept to Clinical Applications. Adv. Drug Deliv. Rev. 2013, 65, 36–48.

7. Has, C.; Sunthar, P. A Comprehensive Review on Recent Preparation Techniques of Liposomes. J. Liposome Res. 2019, 1–30, doi:10.1080/08982104.2019.1668010.

8. He, H.; Lu, Y.; Qi, J.; Zhu, Q.; Chen, Z.; Wu, W. Adapting Liposomes for Oral Drug Delivery. Acta Pharm. Sin. B. 2019, 9, 36–48.

9. Wearley, L.L. Recent Progress in Protein and Peptide Delivery by Noninvasive Routes. Crit. Rev. Ther. Drug Carrier Syst. 1991, 8, 331–394.

10. Fong, S.Y.; Brandl, M.; Bauer-Brandl, A. Phospholipid-Based Solid Drug Formulations for Oral Bioavailability Enhancement: A Meta-Analysis. Eur. J. Pharm. Sci. 2015, 80, 89–110.

11. Albertsson, A.C., Donaruma, L.G., Vogl, O. Synthetic polymers as drugs, In Tirrell, D.A., Donaruma, L.G., Turek, 61 Vol. 6, Issue 2 | magazine.pharmatutor.org PharmaTutor PRINT ISSN: 2394-6679 | E-ISSN: 2347-7881 A.B., (Eds.), Macromolecules as drugs and drug as carriers for biologically active material. Ann NY Acad Sci. 1985; 446: 105-115.

12. Donaruma, L.G., Warner, R.J. Some biologically active (thiosemicarbazides). In Tirrell, D.A., Donaruma, L.G. and Turek, A.B. (Eds.), Macromolecules as drugs and drug as carriers for biologically active materials. Ann NY Acad Sci. 1985; 446: 116-133.

13. Abra, R.M., Hunt, C.A. Liposome disposition in vivo. III. Dose and vesicle size effects, Biochim Biophys Acta. 1981; 666: 493-503.

14. Riaz M: Liposome preparation method. Pak J Pharm Sci 1996, 9(1):65–77.

15. Himanshu A, Sitasharan P, Singhai AK: Liposomes as drug carriers. IJPLS 2011, 2(7):945–951

16. D.J.A Crommelin. Liposomes, Lasic, D.D., Papahadjopoulos, D., 1995. Liposomes revisited.

Science 267, 1275 1276.

17. Emanuel, N., Kedar, E., Bolotin, E.M., Smorodinsky, N.I.,Barenholz, Y., 1996. Preparation and characterization ofdoxorubicin-loaded sterically stabilized immunoliposomes.Pharm. Res. 13, 352-359.

18. Jain N.K. Controlled and Novel Drug Delivery. CBS Publisher, Page no. 304-326.

19 .Kersten, G.F.A., Crommelin, D.J.A., 1995. Liposomes and ISCOMS as vaccine formulations. Biochim. Biophys. Acta 1241, 117-138.

20 .K. Horton. Disertation for degree of Advanced Studies in Chemical Engineering, Universitat Rovira I Virgili, 2003.

21. Remington. The Science and Practice of Pharmacy. Volume I, 21st Edition, B.I Publishers Pvt Ltd, Page no. 314-316.

22. Shargel Leon. Applied Biopharmaceutics and Pharmacokinetics. 5th Edition.page no 214-218.

23. Telange, D.R.; Patil, A.T.; Pethe, A.M.; Fegade, H.; Anand, S.; Dave, V.S. Formulation and Characterization of an Apigenin-Phospholipid Phytosome (APLC) for Improved Solubility, in Vivo Bioavailability, and Antioxidant Potential. Eur. J. Pharm. Sci. 2017, 108, 36–49.

24. El-Zein, H.; Riad, L.; El-Bary, A.A. Enhancement of Carbamazepine Dissolution: In Vitro and in Vivo Evaluation. Int. J. Pharm. 1998, 168, 209–220.

25. Ghassemi, S.; Haeri, A.; Shahhosseini, S.; Dadashzadeh, S. Labrasol-Enriched Nanoliposomal Formulation: Novel Approach to Improve Oral Absorption of Water-Insoluble Drug, Carvedilol. AAPS PharmSciTech. 2018, 19, 2961–2970.

26. Kim, J.H.; Shin, D.H.; Kim, J.S.; Preparation, Characterization, and Pharmacokinetics of Liposomal Docetaxel for Oral Administration. Arch. Pharm. Res. 2018, 41, 765–775.

27. Kovvasu, S.P.; Kunamaneni, P.; Yeung, S.; Rueda, J.; Betageri, G.V. Formulation of Dronedarone Hydrochloride-Loaded Proliposomes: In Vitro and in Vivo Evaluation using Caco-2 and Rat Model. AAPS PharmSciTech 2019, 20, 226.

28. Chen, Y.; Lu, Y.; Chen, J.; Lai, J.; Sun, J.; Hu, F.; Wu, W. Enhanced Bioavailability of the Poorly WaterSoluble Drug Fenofibrate by using Liposomes Containing a Bile Salt. Int. J. Pharm. 2009, 376, 153–160.

29. Youssef, S.F.; Elnaggar, Y.S.; Abdallah, O.Y. Elaboration of Polymersomes Versus Conventional Liposomes for Improving Oral Bioavailability of the Anticancer Flutamide. Nanomedicine 2018, 13, 3025–3036.

30. Brocks, D.R.; Betageri, G.V. Enhanced Oral Absorption of Halofantrine Enantiomers After Encapsulation in a Proliposomal Formulation. J. Pharm. Pharmacol. 2002, 54, 1049–1053. Pharmaceutics 2020, 12, 264 26 of 30

31. Sugihara, H.; Yamamoto, H.; Kawashima, Y.; Takeuchi, H. Effectiveness of Submicronized ChitosanCoated Liposomes in Oral Absorption of Indomethacin. J. Liposome Res. 2012, 22, 72–79. 32. Bobbala, S.K.; Veerareddy, P.R.; Formulation, Evaluation, and Pharmacokinetics of Isradipine Proliposomes for Oral Delivery. J. Liposome Res. 2012, 22, 285–294.

33. Yanamandra, S.; Venkatesan, N.; Kadajji, V.G.; Wang, Z.; Issar, M.; Betageri, G.V. Proliposomes as a Drug Delivery System to Decrease the Hepatic First-Pass Metabolism: Case Study using a Model Drug. Eur. J. Pharm. Sci. 2014, 64, 26–36.

34. Nekkanti, V.; Rueda, J.; Wang, Z.; Betageri, G.V. Comparative Evaluation of Proliposomes and Self MicroEmulsifying Drug Delivery System for Improved Oral Bioavailability of Nisoldipine. Int. J. Pharm. 2016, 505, 79–88.

35. Mirza, S.; Miroshnyk, I.; Habib, M.J.; Brausch, J.F.; Hussain, M.D. Enhanced Dissolution and Oral Bioavailability of Piroxicam Formulations: Modulating Effect of Phospholipids. Pharmaceutics 2010, 2, 339– 350.

36. Velpula, A.; Jukanti, R.; Janga, K.Y.; Sunkavalli, S.; Bandari, S.; Kandadi, P.; Veerareddy, P.R. Proliposome Powders for Enhanced Intestinal Absorption and Bioavailability of Raloxifene Hydrochloride: Effect of Surface Charge. Drug Dev. Ind. Pharm. 2013, 39, 1895–1906.

37. Zhao, M.; Lee, S.H.; Song, J.G.; Kim, H.Y.; Han, H.K. Enhanced Oral Absorption of Sorafenib Via the Layerby-Layer Deposition of a pH-Sensitive Polymer and Glycol Chitosan on the Liposome. Int. J. Pharm. 2018, 544, 14–20.

38. Yan-yu, X.; Yun-mei, S.; Zhi-peng, C.; Qi-neng, P. Preparation of Silymarin Proliposome: A New Way to Increase Oral Bioavailability of Silymarin in Beagle Dogs. Int. J. Pharm. 2006, 319, 162–168.

39. Chu, C.; Tong, S.S.; Xu, Y.; Wang, L.; Fu, M.; Ge, Y.R.; Yu, J.N.; Xu, X.M. Proliposomes for Oral Delivery of Dehydrosilymarin: Preparation and Evaluation in Vitro and in Vivo. Acta Pharmacol. Sin. 2011, 32, 973–980.

40. Nekkanti, V.; Rueda, J.; Wang, Z.; Betageri, G.V.; Design, Characterization, and in Vivo Pharmacokinetics of Tacrolimus Proliposomes. AAPS PharmSciTech 2016, 17, 1019–1029.

41. Xu, H.; He, L.; Nie, S.; Guan, J.; Zhang, X.; Yang, X.; Pan, W. Optimized Preparation of Vinpocetine Proliposomes by a Novel Method and in Vivo Evaluation of its Pharmacokinetics in New Zealand Rabbits. J. Control. Release 2009, 140, 61–68.

42. Janga, K.Y.; Jukanti, R.; Velpula, A.; Sunkavalli, S.; Bandari, S.; Kandadi, P.; Veerareddy, P.R. Bioavailability Enhancement of Zaleplon Via Proliposomes: Role of Surface Charge. Eur. J. Pharm. Biopharm. 2012, 80, 347– 357.

43. Li, C.; Zhang, Y.; Su, T.; Feng, L.; Long, Y.; Chen, Z. Silica-Coated Flexible Liposomes as a Nanohybrid Delivery System for Enhanced Oral Bioavailability of Curcumin. Int. J. Nanomedicine 2012, 7, 5995–6002.

44. Chen, H.; Wu, J.; Sun, M.; Guo, C.; Yu, A.; Cao, F.; Zhao, L.; Tan, Q.; Zhai, G. N-Trimethyl Chitosan Chloride-Coated Liposomes for the Oral Delivery of Curcumin. J. Liposome Res. 2012, 22, 100–109. 45. Tian, M.P.; Song, R.X.; Wang, T.; Sun, M.J.; Liu, Y.; Chen, X.G. Inducing Sustained Release and Improving Oral Bioavailability of Curcumin Via Chitosan Derivatives-Coated Liposomes. Int. J. Biol. Macromol. 2018, 120, 702–710.

46. Shah, N.M.; Parikh, J.; Namdeo, A.; Subramanian, N.; Bhowmick, S.; Preparation, Characterization and in Vivo Studies of Proliposomes Containing Cyclosporine A. J. Nanosci. Nanotechnol. 2006, 6, 2967–2973.

47. Guan, P.; Lu, Y.; Qi, J.; Niu, M.; Lian, R.; Hu, F.; Wu, W. Enhanced Oral Bioavailability of Cyclosporine A by Liposomes Containing a Bile Salt. Int. J. Nanomed. 2011, 6, 965–974.

48. Deng, J.; Zhang, Z.; Liu, C.; Yin, L.; Zhou, J.; Lv, H. The Studies of N-Octyl-N-Arginine-Chitosan Coated Liposome as an Oral Delivery System of Cyclosporine A. J. Pharm. Pharmacol. 2015, 67, 1363–1370.

49. Chen, D.; Xia, D.; Li, X.; Zhu, Q.; Yu, H.; Zhu, C.; Gan, Y. Comparative Study of Pluronic((R)) F127-Modified Liposomes and Chitosan-Modified Liposomes for Mucus Penetration and Oral Absorption of Cyclosporine A in Rats. Int. J. Pharm. 2013, 449, 1–9.

50. Wang, Q.; Liu, W.; Wang, J.; Liu, H.; Chen, Y. Preparation and Pharmacokinetic Study of Daidzein LongCirculating Liposomes. Nanoscale Res. Lett. 2019, 14, 321-331.

51. Patel, G.M.; Shelat, P.K.; Lalwani, A.N. QbD Based Development of Proliposome of Lopinavir for Improved Oral Bioavailability. Eur. J. Pharm. Sci. 2017, 108, 50–61.

Jain, S.; Kumar, D.; Swarnakar, N.K.; Thanki, K. Polyelectrolyte Stabilized Multi-layered Liposomes for Oral Delivery of Paclitaxel. Biomaterials 2012, 33, 6758–6768..

Downloads

Published

2025-12-12

How to Cite

1.
raghubhai B sandipkumar, Verma J. A Complete Review On Liposome Based Delivery Of Water-Soluble Drugs. J Neonatal Surg [Internet]. 2025 Dec. 12 [cited 2026 May 9];14(33S):1045-57. Available from: https://jneonatalsurg.com/index.php/jns/article/view/10248

Issue

Vol. 14 No. 33S (2025): Journal of Neonatal Surgery

Section

Original Article

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

  • Adapt — remix, transform, and build upon the material for any purpose, even commercially.

Terms:

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.